GEN Exclusives

More »

GEN News Highlights

More »
Jun 5, 2008

LabCorp Signs On to Develop Diagnostics Related to Vanda’s Schizophrenia Drug

  • Laboratory Corporation of America and Vanda Pharmaceuticals have partnered to develop and commercialize a series of diagnostic tests for genetic markers identified by Vanda in the course of its clinical development of Fanapta™ (iloperidone). This lead product candidate is an atypical antipsychotic for which the company recently submitted an NDA.

    Vanda has identified a series of pharmacogenetic markers during the development of Fanapta. Under the terms of the collaboration, LabCorp will be Vanda's exclusive commercialization partner for tests for genetic markers of the Fanapta program.

    “Working with innovative companies like Vanda to commercialize predictive medicine tests is a critical strategic focus for LabCorp,” remarks Andrew J. Conrad, Ph.D., chief scientist and global head of clinical trials for LabCorp. “This collaboration represents a successful translation of a research-based assay into a valuable diagnostic test.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Children and Antipsychotic Drugs

Do you think children and adolescents with behavioral problems are overmedicated?